Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BAX 826 in Severe Hemophilia A
NCT02716194Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 1, open-label trial of BAX 826 in hemophilia A (3 cohorts), sponsored by Takeda. Primary endpoints: Serious AEs (SAEs) and Non-serious AEs Occurring After Infusion With BAX 826, Immediate Tolerability (Vital Signs and Clinical Laboratory Assessments) up to 6 weeks and 2 more. Started Mar 2016; status: completed.
02
Drugs
BAX 826
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02716194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716194.